Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study

BACKGROUND: COVID-19 disproportionately impacted patients with cancer as a result of direct infection, and delays in diagnosis and therapy. Oncological clinical trials are resource-intensive endeavors that could be particularly susceptible to disruption by the pandemic, but few studies have evaluate...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakouny, Z., Labaki, C., Bhalla, S., Schmidt, A.L., Steinharter, J.A., Cocco, J., Tremblay, D.A., Awad, M.M., Kessler, A., Haddad, R.I., Evans, M., Busser, F., Wotman, M., Curran, C.R., Zimmerman, B.S., Bouchard, G., Jun, T., Nuzzo, P.V., Qin, Q., Hirsch, L., Feld, J., Kelleher, K.M., Seidman, D., Huang, H., Anderson-Keightly, H.M., El Zarif, T., Alaiwi, S. Abou, Champagne, C., Rosenbloom, T.D., Stewart, P.S., Johnson, B.E., Trinh, Q., Tolaney, S.M., Galsky, M.D., Choueiri, T.K., Doroshow, D.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society for Medical Oncology. Published by Elsevier Ltd. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197329/
https://www.ncbi.nlm.nih.gov/pubmed/35715285
http://dx.doi.org/10.1016/j.annonc.2022.04.071

Ejemplares similares

Ejemplares similares